Nipent (Pentostatin)

Pentostatin inhibits adenosine deaminase, an enzyme essential for purine metabolism. This inhibition leads to the buildup of deoxyadenosine nucleotides inside lymphocytes, disrupting DNA synthesis and triggering programmed cell death (apoptosis) of the malignant B‑cell population.

The dosing regimen for Nipent is individualized by the prescribing physician based on the patient’s disease characteristics, body surface area, renal function, and treatment response. Only a qualified healthcare professional should determine the appropriate dose and schedule.

Pentostatin is classified as contraindicated in pregnancy because it can cause fetal harm. Women of childbearing potential should use effective contraception. Breastfeeding is not recommended while receiving treatment, as the drug may be excreted in milk and affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed) and the necessary import documentation.

Pentostatin belongs to the purine analog class, differing from alkylating agents or monoclonal antibodies. Compared with fludarabine, another antimetabolite, pentostatin has a distinct mechanism—adenosine deaminase inhibition—resulting in a unique toxicity profile, especially a higher incidence of severe myelosuppression but lower rates of neurotoxicity.

Nipent must be stored refrigerated at 2‑8 °C. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking. If the product reaches room temperature for a short period, it should be returned to the refrigerator promptly.

Nipent is supplied as a sterile injectable solution for intravenous infusion. It is administered by a qualified healthcare professional, typically over a period of several minutes to an hour, depending on the prescribed dose and infusion protocol.

The most serious risks include severe bone‑marrow suppression leading to neutropenia, anemia or thrombocytopenia, which can precipitate life‑threatening infections or bleeding. Pulmonary toxicity and hepatic dysfunction are also rare but potentially fatal complications that require immediate medical attention.

Patients with active severe infections, uncontrolled hepatic or renal impairment, or those who have received recent live vaccines should avoid pentostatin. Additionally, pregnant or breastfeeding women, and individuals with known hypersensitivity to pentostatin or any excipients in the formulation, should not be treated with Nipent.